Oxford, UK – 12th April 2018 – OxSonics co-founder Professor Robert Carlisle is an invited speaker at the 2018 International Oncolytic Virus Congress and will be speaking on the subject of “Enhanced Delivery of Oncolytic Viruses into and Throughout Tumours”. The congress is attended by the world’s leading academic groups and companies developing ground-breaking oncolytic viral therapies. Presentations covering both pre-clinical and numerous clinical stage investigations will be reported at the meeting. Professor Robert Carlisle commented: “The invitation to present at this highly prestigious congress underscores the compelling data that OxSonics and its collaborators have generated to date. Although the SonoTran® platform can be applied to any class of oncology agent, the impact that SonoTran can have on the activity of oncolytic viruses can be most profound where the virus is replicating. In pre-clinical models, the SonoTran platform has been shown to yield up to a 10,000-fold increase in activity by improving the tumour dose and distribution of the virus.”
A link to the congress website is shown here: https://iovc.ada.wats-on.co.uk/Home.aspx
– ENDS –
About OxSonics® Limited
OxSonics® was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics SonoTran® drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics® is based in Oxford, UK.
For more information please visit: www.oxsonics.com